These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33032771)

  • 1. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
    Husni ME; Kavanaugh A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Harrison DD; Han C
    Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
    Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
    Ogdie A; Walsh JA; Chakravarty SD; Peterson S; Lo KH; Kim L; Li N; Hsia EC; Chan EKH; Kavanaugh A; Husni ME
    Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
    Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB
    Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V; Schett G; Hu C; Stevens RM
    J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
    Kavanaugh A; Antoni C; Krueger GG; Yan S; Bala M; Dooley LT; Beutler A; Guzzo C; Gladman D
    Ann Rheum Dis; 2006 Apr; 65(4):471-7. PubMed ID: 16096330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
    Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
    Kavanaugh A; Mease P
    J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.
    Strand V; Alemao E; Lehman T; Johnsen A; Banerjee S; Ahmad HA; Mease PJ
    Arthritis Res Ther; 2018 Dec; 20(1):269. PubMed ID: 30522501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.
    Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C;
    Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
    Husni ME; Kavanaugh A; Murphy F; Rekalov D; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):806-813. PubMed ID: 30980514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.